Literature DB >> 15755865

Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire.

Susannah V Rowles1, L Prieto, X Badia, Steven M Shalet, Susan M Webb, Peter J Trainer.   

Abstract

Acromegaly Quality of Life Questionnaire (AcroQoL) is a new disease-generated quality of life (QOL) questionnaire comprising 22 questions covering physical and psychological aspects of acromegaly and subdivided into "appearance" and "personal relations" categories. We have performed a cross-sectional study of QOL in 80 patients [43 male (mean age, 54.2 yr; range, 20-84); median GH, 0.93ng/ml (range, <0.3 to 23.7); IGF-I, 333.1 ng/ml (range, 47.7-899)] with acromegaly. In addition to AcroQoL, patients completed three generic QOL questionnaires: Psychological General Well-Being Schedule (PGWBS), EuroQol, and a signs and symptoms score (SSS). All three generic questionnaires confirmed impairment in QOL [mean scores: PGWBS, 69.6; EuroQol, visual analog scale, 66.4 (range, 20-100) and utility index, 0.7 (range, -0.07 to 0.92); and SSS, 12 (range, 0-27)]. There was no correlation between biochemical control and any measure of QOL. AcroQoL (57.3%; range, 18.2-93.2) correlated with PGWBS (r = 0.73; P < 0.0001); and in patients with active disease, AcroQoL-physical dimension correlated with SSS (r = -0.67; P < 0.0003). In all questionnaires, prior radiotherapy was associated with impaired QOL. In conclusion, these data underline the marked impact that acromegaly has on patients' QOL and provide the first evidence validating AcroQoL against well-authenticated measures of QOL. This indicates the potential of AcroQoL as a patient-friendly measure of disease activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755865     DOI: 10.1210/jc.2004-1565

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  44 in total

1.  Biochemical and quality of life responses to octreotide-LAR in acromegaly.

Authors:  Ruth Mangupli; Paul Camperos; Susan M Webb
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

2.  Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire.

Authors:  Silvia Vandeva; Maria Yaneva; Emil Natchev; Atanaska Elenkova; Krasimir Kalinov; Sabina Zacharieva
Journal:  Endocrine       Date:  2015-01-06       Impact factor: 3.633

3.  Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders.

Authors:  Elena Valassi; Danielle J Brick; Jessica C Johnson; Beverly M K Biller; Anne Klibanski; Karen K Miller
Journal:  Endocr Pract       Date:  2012 Mar-Apr       Impact factor: 3.443

Review 4.  Update on quality of life in patients with acromegaly.

Authors:  Iris Crespo; Elena Valassi; Susan M Webb
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Cognitive function in acromegaly: description and brain volumetric correlates.

Authors:  Caroline Sievers; P G Sämann; H Pfister; C Dimopoulou; M Czisch; J Roemmler; J Schopohl; G K Stalla; J Zihl
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

6.  Impact of treatment satisfaction on quality of life of patients with acromegaly.

Authors:  Hasan Kepicoglu; Esra Hatipoglu; Irem Bulut; Ezgi Darici; Naz Hizli; Pinar Kadioglu
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

7.  Psychosocial morbidity in acromegaly: a study from India.

Authors:  Surendra Kumar Mattoo; Anil Kumar Bhansali; Nitin Gupta; Sandeep Grover; Ramma Malhotra
Journal:  Endocrine       Date:  2008-10-25       Impact factor: 3.633

8.  Assessment of balance performance and fear of falling in acromegalic patients: a comparative study.

Authors:  A Atmaca; B Tander; E K Kan; Y Ulus; G C Ecemis; Y Akyol; L Tomak
Journal:  J Endocrinol Invest       Date:  2013-04-23       Impact factor: 4.256

9.  Quality of life in female patients with acromegaly.

Authors:  O Celik; P Kadioglu
Journal:  J Endocrinol Invest       Date:  2012-11-26       Impact factor: 4.256

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.